Skip to : [Content] [Navigation]
Consultants Corner
 

Consultants Corner

Current Issue: November 2009


Finding a Qualified Distributor in Europe
Michael van der Woude, EDM Services

With 500 million people in 27 countries, the European Union is a huge market. It is also a challenging one because of language barriers and differences in business culture. Establishing national distributorships is vital to long-term success. Put the odds in your favor by following these five steps when selecting a distribution partner. Read more.

Global Perspectives
Asia/Pacific: Device Manufacturers in China Face Increased Regulatory Scrutiny
Ames Gross, Pacific Bridge Medical

China’s State Food and Drug Administration (SFDA) continues to ramp up plans to improve quality and increase regulations in the medical device arena. Read more.

European Union: Please Read Carefully: Label and IFU Revisions Take Effect Next Year, Part II
René Clément, MediMark Europe

This is the second of a two-part article on changes to labels and instructions for use (IFU) in Directive 2007/47/EC, which will become law on March 21, 2010. This time we will focus on how devices containing phthalates will be affected. Read more.

North America: Documenting Software in a 510(k) Submission Is a Strategic Decision
Marc Goodman, Senior Consultant , Noblitt & Rueland

Computers, software, and medical devices have become much more complex since I first developed medical device software in the 1980s. Equally important, FDA’s premarket review of software in medical devices has become orders-of-magnitude more rigorous since that time. In 510(k) submissions for devices containing software prepared in the 1980s, the description of the software could consist of a single sentence: The device has software. The software information in a typical 510(k) submission today can easily constitute half of the total submission, if not more. Read more.

 
 

Consultants Corner Archives

September 2009

  • The Importance of Maintaining Compliance in an Uncertain Economy
    In the year since the bottom fell out of the economy, I have seen many clients, large and small, struggle to maintain regulatory compliance. At the same time, FDA’s budget has increased, it is hiring additional resources, has a new commissioner and soon a new director at CDRH, and is promulgating new regulations and guidance documents such as the recent draft guidance, “Presenting Risk Information in Prescription Drugs and Medical Device Promotion.”
  • Global Perspectives: Asia/Pacific: Formal Notification Imminent for Medical Device Regulations in India
    In June 2009, the Drug Consultative Committee (DCC) and the Drug Technical Advisory Board (DTAB) approved new formal regulations for India’s medical device sector. The new regulations, titled Schedule M-III, have been sent to the Ministry of Health for final notification, which is expected soon.
  • Global Perspectives: European Union: Label and IFU Revisions Take Effect Next Year, Part I
    In the past two issues of this newsletter, we published a comprehensive glossary of revisions to Medical Device Directive 93/42/EEC and Active Implantables Medical Device Directive 90/385/EEC. Now, we begin another two-part article focusing on changes to labels and instructions for use (IFU) that will become law on March 21, 2010.
  • Global Perspectives: North America: FDA 510(k) Reviews Becoming More Rigorous
    According to regulation, a new device must demonstrate “substantial equivalence” to receive 510(k) clearance. To establish equivalence, the new device must have the same general intended use as a predicate device. Substantial equivalence determination is also predicated on the technological characteristics of the device. New devices are often designed with patentable differences in technology. These differences can give the edge over the competition, but they can pose challenges in demonstrating “substantial equivalence.” It is the technical differences that give FDA pause, as it must establish whether the new characteristics affect safety or effectiveness.
June 2009

  • A Tale of Two FDA Inspections
    The myopic approach of agency inspectors does a disservice to an increasingly sophisticated industry.
  • Global Perspectives: Asia/Pacific: Korea Set to Revise Product Approval Process
    Korea is an important Asian destination for foreign medical devices. Its total medical device market is about $3 billion. While this may seem low compared with China’s $7.5 billion, Korea’s health expenditure per capita in 2006 was $705 whereas China’s was $61, according to the World Health Organization.
  • Global Perspectives: European Union: Device Directive Revisions Become Law in March 2010—Are You Prepared? Part II
    In the previous Consultants Corner newsletter, we published the first part of a comprehensive glossary of revisions to Medical Device Directive 93/42/EEC and Active Implantables Medical Device Directive 90/385/EEC. In this issue, we continue our review of the revisions beginning with changes involving the declaration of conformity.
  • Global Perspectives: North America: Practical Points to Consider for a Compliant Design Control Process
    FDA continues to cite manufacturers for serious design control violations found during inspections that lead to warning letters. Very recently, a company received a warning letter that included significant design control findings. It suggested the company consider withdrawing a previously cleared 510(k) if it is found to have unreliable or unverifiable data. Imagine the impact to your company if you had to remove a major product from the market because a 510(k) had to be withdrawn. We have put together some practical points to consider when implementing and maintaining a compliant design control process.
March 2009

January 2009
November 2008
  • Electronic Data Capture in Clinical Trials: Four Factors for Success
    Real-time data access and automated edit checks are just two of the many benefits that EDC can bring to clinical trial management.
  • Q&A: FDA and ISO Guidance

    Guidance for device makers who voluntarily submit ISO audit reports has been delayed by FDA until the end of this year. Will the agency make its new deadline? We asked Nicolaas C. Besseling, principal, BesTech Consulting Services, about that and some related matters.

Fall 2008
  • Chapter and Verse on SOPs
    Take a commonsense approach: writing overly restrictive SOPs can lead your company into trouble.
  • Q&A: Regulatory Reform in Japan: Is It Change We Can Believe In?
    Ames Gross, president and founder of Pacific Bridge Medical, has helped more than 200 medical device companies navigate the often-tortuous business and regulatory practices of countries in the Asia/Pacific region. In this Q&A, he offers some insights on Japan’s regulatory approval process.
Summer 2008
Spring 2008
Winter 2008